anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Magnesium Sulfate
Trial phase: Phase 3
ATC code: A06AD04 | A12CC02 | B05XA05 | D11AX05 | V04CC02
SMILES: O=S(=O)([O-])[O-].[Mg+2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 243
Group description: FDA approved bowel preparation solution for oral ingestion

Bowel Prep: Orally ingested liquid bowel preparation
Eligibility criteria:
Inclusion Criteria:

Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.
18 to 85 years of age (inclusive)
If female, and of child-bearing potential, is using an acceptable form of birth control.
Negative serum pregnancy test at screening, if applicable
In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

Exclusion Criteria:

Subjects with known or suspected ileus, gastrointestinal obstruction, gastroparesis, gastric retention, bowel perforation, toxic colitis or megacolon.
Subjects with inflammatory bowel disease who have a history of any bowel resection (small intestine or colon), suspected active inflammation, or symptoms suggestive of obstruction or known bowel stricture.
Subjects who had previous significant gastrointestinal surgeries.
Subjects who have regularly used laxatives or colon motility altering drugs in the last month (i.e. more than 2-3 times per week) and/or laxative use within 72 hours prior to administration of the preparation
Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.
Subjects taking diuretics, anti-hypertensive medications, including angiotensin converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs), or chronic NSAIDs, that have not been stable for 30 days.
Subjects with uncontrolled hypertension.
Subjects taking antibiotics within 7 days of colonoscopy.
Subjects with severe renal, hepatic or cardiac insufficiency.
Subjects with an abnormal and clinically significant physical examination or ECG finding at Visit 1.
Subjects undergoing insulin therapy for any indication.
Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
Subjects undergoing colonoscopy for foreign body removal and/or decompression.
Subjects taking tricyclic antidepressants.
Subjects using drugs of abuse, including abused prescription medications.
Subjects who are withdrawing from alcohol or benzodiazepines.
Intervention: Magnesium Sulfate
Trial phase: Phase 3
ATC code: A06AD04 | A12CC02 | B05XA05 | D11AX05 | V04CC02
SMILES: O=S(=O)([O-])[O-].[Mg+2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 227
Group description: Experimental bowel preparation solution for oral ingestion

Bowel Prep: Orally ingested liquid bowel preparation
Eligibility criteria:
Inclusion Criteria:

Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.
18 to 85 years of age (inclusive)
If female, and of child-bearing potential, is using an acceptable form of birth control.
Negative serum pregnancy test at screening, if applicable
In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

Exclusion Criteria:

Subjects with known or suspected ileus, gastrointestinal obstruction, gastroparesis, gastric retention, bowel perforation, toxic colitis or megacolon.
Subjects with inflammatory bowel disease who have a history of any bowel resection (small intestine or colon), suspected active inflammation, or symptoms suggestive of obstruction or known bowel stricture.
Subjects who had previous significant gastrointestinal surgeries.
Subjects who have regularly used laxatives or colon motility altering drugs in the last month (i.e. more than 2-3 times per week) and/or laxative use within 72 hours prior to administration of the preparation
Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.
Subjects taking diuretics, anti-hypertensive medications, including angiotensin converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs), or chronic NSAIDs, that have not been stable for 30 days.
Subjects with uncontrolled hypertension.
Subjects taking antibiotics within 7 days of colonoscopy.
Subjects with severe renal, hepatic or cardiac insufficiency.
Subjects with an abnormal and clinically significant physical examination or ECG finding at Visit 1.
Subjects undergoing insulin therapy for any indication.
Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
Subjects undergoing colonoscopy for foreign body removal and/or decompression.
Subjects taking tricyclic antidepressants.
Subjects using drugs of abuse, including abused prescription medications.
Subjects who are withdrawing from alcohol or benzodiazepines.
Intervention: Magnesium Sulfate
Trial phase: Phase 3
ATC code: A06AD04 | A12CC02 | B05XA05 | D11AX05 | V04CC02
SMILES: O=S(=O)([O-])[O-].[Mg+2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 226
Group description: FDA approved bowel preparation solution for oral ingestion

Bowel Prep: Orally ingested liquid bowel preparation
Eligibility criteria:
Inclusion Criteria:

Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.
18 to 85 years of age (inclusive)
If female, and of child-bearing potential, is using an acceptable form of birth control.
Negative serum pregnancy test at screening, if applicable
In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

Exclusion Criteria:

Subjects with known or suspected ileus, gastrointestinal obstruction, gastroparesis, gastric retention, bowel perforation, toxic colitis or megacolon.
Subjects with inflammatory bowel disease who have a history of any bowel resection (small intestine or colon), suspected active inflammation, or symptoms suggestive of obstruction or known bowel stricture.
Subjects who had previous significant gastrointestinal surgeries.
Subjects who have regularly used laxatives or colon motility altering drugs in the last month (i.e. more than 2-3 times per week) and/or laxative use within 72 hours prior to administration of the preparation
Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.
Subjects taking diuretics, anti-hypertensive medications, including angiotensin converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs), or chronic NSAIDs, that have not been stable for 30 days.
Subjects with uncontrolled hypertension.
Subjects taking antibiotics within 7 days of colonoscopy.
Subjects with severe renal, hepatic or cardiac insufficiency.
Subjects with an abnormal and clinically significant physical examination or ECG finding at Visit 1.
Subjects undergoing insulin therapy for any indication.
Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
Subjects undergoing colonoscopy for foreign body removal and/or decompression.
Subjects taking tricyclic antidepressants.
Subjects using drugs of abuse, including abused prescription medications.
Subjects who are withdrawing from alcohol or benzodiazepines.
Intervention: Proxalutamide
Trial phase: Not Applicable
SMILES: CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2F)C(=S)N1c1ccc(CCCc2ncco2)nc1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 134
Group description: Proxalutamide + usual care as determined by the PI

Proxalutamide: 200 mg q.d.
Eligibility criteria:
Inclusion Criteria:

Male age ≥18 years old
Laboratory confirmed positive SARS-CoV-2 rtPCR test within 7 days prior to randomization
Clinical status on the COVID-19 8-point Ordinal Scale of 1 or 2
Coagulation: INR ≤ 1.5×ULN, and APTT ≤ 1.5×ULN
Subject (or legally authorized representative) gives written informed consent prior to any study screening procedures
Subject (or legally authorized representative) agree that subject will not participate in another COVID-19 trial while participating in this study

Exclusion Criteria:

Subject enrolled in a study to investigate a treatment for COVID-19
Subject taking an anti-androgen of any type including: androgen depravation therapy, 5-alpha reductase inhibitors, etc…
Patients who are allergic to the investigational product or similar drugs (or any excipients);
Subjects who have malignant tumors in the past 5 years, with the exception of completed resected basal cell and squamous cell skin cancer and completely resected carcinoma in situ of any type
Subjects with known serious cardiovascular diseases, congenital long QT syndrome, torsade de pointes, myocardial infarction in the past 6 months, or arterial thrombosis, or unstable angina pectoris, or congestive heart failure which is classified as New York Heart Association (NYHA) class 3 or higher, or left ventricular ejection fraction (LVEF) < 50%, QTcF > 450 ms
Subjects with uncontrolled medical conditions that could compromise participation in the study(e.g. uncontrolled hypertension, hypothyroidism, diabetes mellitus)
Known diagnosis of human immunodeficiency virus(HIV) , hepatitis C, active hepatitis B, treponema pallidum (testing is not mandatory）
Alanine Transaminase (ALT) or Aspartate Transaminase (AST) > 5 times the upper limit of normal.
Estimated glomerular filtration rate (eGFR) < 30 ml/min
Severe kidney disease requiring dialysis
Subject unlikely to return for day 15 site visit for reasons other then remission
Subject (or legally authorized representative) not willing or unable to provide informed consent
Intervention: ASCORBIC ACID
Trial phase: Phase 2
ATC code: A11GA01 | A11GB01 | B03AA10 | G01AD03 | S01XA15
SMILES: O=C1OC(C(O)CO)C(O)=C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 51
Group description: Oral C21 treatment 100 mg twice daily for 7 days
Eligibility criteria:
Inclusion Criteria:

Written informed consent, consistent with ICH-GCP R2 and local laws, obtained before the initiation of any trial related procedure
Diagnosis of coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) test < 4 days before Visit 1 with signs of an acute respiratory infection
Age > 18 and < 70 years
CRP > 50 and < 150 mg/l
Admitted to a hospital or controlled facility (home quarantine is not sufficient)
In the opinion of the Investigator, the subject will be able to comply with the requirements of the protocol

Exclusion Criteria:

Any previous experimental treatment for COVID-19
Need for mechanical invasive or non-invasive ventilation
Concurrent respiratory disease such as COPD (chronic obstructive pulmonary disease), IPF and/or intermittent, persistent or more severe asthma requiring daily therapy or any subjects that have had an asthma flare requiring corticosteroids in the 4 weeks (28 days) prior to COVID-19 diagnosis
Participation in any other interventional trial within 3 months prior to Visit 1

Any of the following findings at Visit 1:

Positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb) or human immunodeficiency virus 1+2 antigen/antibody (HIV 1+2 Ag/Ab
Positive pregnancy test (see Section 8.2.3)
Clinically significant abnormal laboratory value at Visit 1 indicating a potential risk for the subject if enrolled in the trial as evaluated by the Investigator
Concurrent serious medical condition with special attention to cardiac or ophthalmic conditions (e.g. contraindications to cataract surgery), which in the opinion of the Investigator makes the subject inappropriate for this trial
Malignancy within the past 3 years with the exception of in situ removal of basal cell carcinoma and cervical intraepithelial neoplasia grade I

Treatment with any of the medications listed below within 1 week prior to Visit 1:

Strong Cytochrome p450 (CYP) 3A4 inducers (e.g. rifampicin, phenytoin, St. John's Wort, phenobarbital, rifabutin, carbamazepine, anti HIV drugs, barbiturates)
Warfarin
Pregnant or breast-feeding female subjects
Female subjects of childbearing potential not willing to use contraceptive methods as described in Section 5.3.1
Male subjects not willing to use contraceptive methods as described in Section 5.3.1
Subjects known or suspected of not being able to comply with this trial protocol (e.g. due to alcoholism, drug dependency or psychological disorder)
Intervention: Etonogestrel
Trial phase: Phase 4
ATC code: G03AC08
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@@]21[H]
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 5
Group description: Insertion of the etonogestrel contraceptive implant subdermally over the non-dominant scapula

Etonogestrel implant: Insertion of the contraceptive implant at an alternative insertion site located over the scapula
Eligibility criteria:
Inclusion Criteria:

Healthy women

Exclusion Criteria:

Any contraindications to etonogestrel implant use based on the US Medical Eligibility Criteria for Contraceptive use (defined as class 3 or 4 recommendation)18
Any known liver conditions that could affect drug metabolism (e.g. cirrhosis, hepatitis)
Currently taking any medications or supplements known to be CYP3A4 inducers/inhibitors19
Body-mass index less than 18.5kg/m2 or greater than 30kg/m2
Currently pregnant or planning to become pregnant in the next 12 months
Intervention: Melatonin
Trial phase: Phase 2
ATC code: N05CH01
SMILES: COc1ccc2[nH]cc(CCNC(C)=O)c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.

Melatonin: Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
Eligibility criteria:
Inclusion Criteria:

Male or non-pregnant female adult ≥18 years of age at time of enrollment.
Women of childbearing potential must agree to use at least one primary form of contraception for the duration of the study.
Subject provides written informed consent prior to initiation of any study procedures.
Understands and agrees to comply with planned study procedures.
Agrees to the collection and storage of saliva samples per protocol.

Exclusion Criteria:

Severe chronic liver disease
Severe chronic kidney disease or requiring dialysis
Pregnancy or breast feeding.
Allergy to the study medication
Currently taking melatonin
Currently taking high dose (>500 mg/day) Vitamin C
Intervention: Dalzanemdor
Trial phase: Phase 2
SMILES: CC(CCC(C)(O)C(F)(F)F)C1CCC2C3CC=C4CC(C)(O)CCC4(C)C3CCC12C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Participants received SAGE-718 3 mg tablets, once daily with food in the morning for 14 days in Part A of study.
Eligibility criteria:
Inclusion Criteria:

Meet the following criteria for PD-MCI: Have a confirmed diagnosis of idiopathic PD according to 2015 Movement Disorder Society (MDS) clinical diagnostic criteria; Meet MDS Task Force Criteria for MCI in PD.
Have a score of 20 to 25 (inclusive) on the Montreal Cognitive Assessment (MoCA) at Screening.
Meet criteria for Hoehn & Yahr Stage I to III (mild to moderate motor severity) at Screening.
Have stable motor symptoms for at least 4 weeks prior to screening, in the opinion of the investigator.

Exclusion Criteria:

Have a diagnosis of dementia of any etiology, including but not limited to: Dementia associated with PD (probable or possible), Dementia with Lewy Bodies, Alzheimer's Dementia, and Vascular Dementia.
Have any indication of parkinsonism other than idiopathic PD.
In the opinion of the investigator, be experiencing unpredictable fluctuations in motor and/or nonmotor symptoms associated with PD.
Have an ongoing central nervous system condition other than idiopathic PD, including active neurologic and/or nonremitted psychiatric disorders, in the opinion of the investigator.
Have a history of brain surgery, deep brain stimulation, a significant head injury causing loss of consciousness greater than 30 minutes, or hospitalization due to a brain injury.
Have experienced significant psychotic symptoms within the past 3 months, including those associated with PD medications, as determined by the investigator.
Intervention: Dalzanemdor
Trial phase: Phase 2
SMILES: CC(CCC(C)(O)C(F)(F)F)C1CCC2C3CC=C4CC(C)(O)CCC4(C)C3CCC12C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Participants received SAGE-718 3 mg tablets, once daily with food in the morning for 28 days in Part B of study.
Eligibility criteria:
Inclusion Criteria:

Meet the following criteria for PD-MCI: Have a confirmed diagnosis of idiopathic PD according to 2015 Movement Disorder Society (MDS) clinical diagnostic criteria; Meet MDS Task Force Criteria for MCI in PD.
Have a score of 20 to 25 (inclusive) on the Montreal Cognitive Assessment (MoCA) at Screening.
Meet criteria for Hoehn & Yahr Stage I to III (mild to moderate motor severity) at Screening.
Have stable motor symptoms for at least 4 weeks prior to screening, in the opinion of the investigator.

Exclusion Criteria:

Have a diagnosis of dementia of any etiology, including but not limited to: Dementia associated with PD (probable or possible), Dementia with Lewy Bodies, Alzheimer's Dementia, and Vascular Dementia.
Have any indication of parkinsonism other than idiopathic PD.
In the opinion of the investigator, be experiencing unpredictable fluctuations in motor and/or nonmotor symptoms associated with PD.
Have an ongoing central nervous system condition other than idiopathic PD, including active neurologic and/or nonremitted psychiatric disorders, in the opinion of the investigator.
Have a history of brain surgery, deep brain stimulation, a significant head injury causing loss of consciousness greater than 30 minutes, or hospitalization due to a brain injury.
Have experienced significant psychotic symptoms within the past 3 months, including those associated with PD medications, as determined by the investigator.
Intervention: POVORCITINIB
Trial phase: Phase 2
SMILES: Cc1n[nH]c(C)c1-c1cnn(C2(CC#N)CN(c3cc(F)c(C(=O)N[C@@H](C)C(F)(F)F)cc3F)C2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: Participants received oral INCB054707 15 milligrams (mg) QD for 16 weeks in the Placebo-controlled Treatment Period.
Eligibility criteria:
Inclusion Criteria:

HS disease duration of at least 3 months before screening.
Willingness to avoid pregnancy or fathering children.
Active HS in at least 2 distinct anatomical areas.
Participants agree NOT to use topical antiseptics on the areas affected by HS lesions during the placebo-controlled 16-week treatment period

Exclusion Criteria:

Draining fistula count of > 20 at screening or baseline.
Women who are pregnant (or who are considering pregnancy) or lactating.
Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
History of failure to treatment of inflammatory diseases with JAK inhibitors.
Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.
Laboratory values outside of the protocol-defined ranges.
Intervention: POVORCITINIB
Trial phase: Phase 2
SMILES: Cc1n[nH]c(C)c1-c1cnn(C2(CC#N)CN(c3cc(F)c(C(=O)N[C@@H](C)C(F)(F)F)cc3F)C2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Participants received oral INCB054707 45 mg QD for 16 weeks in the Placebo-controlled Treatment Period.
Eligibility criteria:
Inclusion Criteria:

HS disease duration of at least 3 months before screening.
Willingness to avoid pregnancy or fathering children.
Active HS in at least 2 distinct anatomical areas.
Participants agree NOT to use topical antiseptics on the areas affected by HS lesions during the placebo-controlled 16-week treatment period

Exclusion Criteria:

Draining fistula count of > 20 at screening or baseline.
Women who are pregnant (or who are considering pregnancy) or lactating.
Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
History of failure to treatment of inflammatory diseases with JAK inhibitors.
Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.
Laboratory values outside of the protocol-defined ranges.
Intervention: POVORCITINIB
Trial phase: Phase 2
SMILES: Cc1n[nH]c(C)c1-c1cnn(C2(CC#N)CN(c3cc(F)c(C(=O)N[C@@H](C)C(F)(F)F)cc3F)C2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: Participants received oral INCB054707 75 mg QD for 16 weeks in the Placebo-controlled Treatment Period.
Eligibility criteria:
Inclusion Criteria:

HS disease duration of at least 3 months before screening.
Willingness to avoid pregnancy or fathering children.
Active HS in at least 2 distinct anatomical areas.
Participants agree NOT to use topical antiseptics on the areas affected by HS lesions during the placebo-controlled 16-week treatment period

Exclusion Criteria:

Draining fistula count of > 20 at screening or baseline.
Women who are pregnant (or who are considering pregnancy) or lactating.
Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
History of failure to treatment of inflammatory diseases with JAK inhibitors.
Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.
Laboratory values outside of the protocol-defined ranges.